Erasca, Inc. ERAS
We take great care to ensure that the data presented and summarized in this overview for Erasca, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ERAS
View all-
Frazier Life Sciences Management, L.P. Menlo Park, CA19.4MShares$55.5 Million2.85% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD16.8MShares$48.1 Million0.03% of portfolio
-
Vr Adviser, LLC New York, NY16.2MShares$46.4 Million4.58% of portfolio
-
Suvretta Capital Management, LLC New York, NY13.8MShares$39.4 Million1.48% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$38 Million0.0% of portfolio
-
Arch Venture Management, LLC Chicago, IL11.1MShares$31.6 Million18.15% of portfolio
-
Logos Global Management LP San Francisco, CA10.9MShares$31.2 Million3.94% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY10.7MShares$30.5 Million1.05% of portfolio
-
Black Rock Inc. New York, NY10.6MShares$30.3 Million0.0% of portfolio
-
Siren, L.L.C. New York, NY8.86MShares$25.3 Million1.21% of portfolio
Latest Institutional Activity in ERAS
Top Purchases
Top Sells
About ERAS
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
Insider Transactions at ERAS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 21
2024
|
Alexander W. Casdin Director |
BUY
Open market or private purchase
|
Direct |
80,000
+12.23%
|
$160,000
$2.27 P/Share
|
|
Dec 15
2023
|
David M. Chacko CFO and CBO |
BUY
Other acquisition or disposition
|
Direct |
7,478
+2.94%
|
$7,478
$1.59 P/Share
|
|
Dec 15
2023
|
Ebun Garner General Counsel & Corp. Sec. |
BUY
Other acquisition or disposition
|
Direct |
5,448
+35.9%
|
$5,448
$1.59 P/Share
|
|
Dec 06
2023
|
Valerie Denise Harding Start Director |
BUY
Open market or private purchase
|
Indirect |
10,000
+33.33%
|
$10,000
$1.85 P/Share
|
|
Dec 06
2023
|
Jonathan E Lim Chairman & CEO |
BUY
Open market or private purchase
|
Indirect |
278,150
+2.11%
|
$278,150
$1.72 P/Share
|
|
Dec 05
2023
|
Jonathan E Lim Chairman & CEO |
BUY
Open market or private purchase
|
Indirect |
721,850
+5.3%
|
$721,850
$1.69 P/Share
|
|
Dec 04
2023
|
Alexander W. Casdin Director |
BUY
Open market or private purchase
|
Direct |
30,000
+5.73%
|
$30,000
$1.66 P/Share
|
|
Oct 05
2023
|
Jonathan E Lim Chairman & CEO |
BUY
Open market or private purchase
|
Indirect |
1,000,000
+4.89%
|
$2,000,000
$2.03 P/Share
|
|
Jun 08
2023
|
Jonathan E Lim Chairman & CEO |
BUY
Open market or private purchase
|
Indirect |
100,000
+0.54%
|
$200,000
$2.75 P/Share
|
|
Apr 10
2023
|
Alexander W. Casdin Director |
BUY
Open market or private purchase
|
Direct |
20,000
+4.13%
|
$40,000
$2.76 P/Share
|
|
Mar 28
2023
|
Jonathan E Lim Chairman & CEO |
BUY
Open market or private purchase
|
Indirect |
100,000
+0.54%
|
$200,000
$2.84 P/Share
|
|
Feb 01
2023
|
David M. Chacko CFO and CBO |
BUY
Other acquisition or disposition
|
Direct |
1,750
+0.36%
|
$5,250
$4.0 P/Share
|
|
Feb 01
2023
|
Ebun Garner General Counsel & Corp. Sec. |
BUY
Other acquisition or disposition
|
Direct |
2,390
+17.93%
|
$7,170
$4.0 P/Share
|
|
Feb 01
2023
|
Lin Wei Chief Medical Officer |
BUY
Other acquisition or disposition
|
Direct |
1,750
+0.28%
|
$5,250
$4.0 P/Share
|
|
Jan 10
2023
|
Jonathan E Lim Chairman & CEO |
BUY
Open market or private purchase
|
Indirect |
60,000
+0.3%
|
$180,000
$3.86 P/Share
|
|
Dec 21
2022
|
James Arthur Bristol Director |
BUY
Open market or private purchase
|
Indirect |
20,000
+50.0%
|
$80,000
$4.14 P/Share
|
|
Dec 21
2022
|
Valerie Denise Harding Start Director |
BUY
Open market or private purchase
|
Indirect |
10,000
+50.0%
|
$40,000
$4.64 P/Share
|
|
Dec 15
2022
|
Alexander W. Casdin Director |
BUY
Open market or private purchase
|
Direct |
20,000
+4.31%
|
$80,000
$4.87 P/Share
|
|
Dec 14
2022
|
Jonathan E Lim Chairman & CEO |
BUY
Open market or private purchase
|
Indirect |
40,000
+0.2%
|
$160,000
$4.99 P/Share
|
|
Dec 13
2022
|
Bihua Chen |
BUY
Open market or private purchase
|
Indirect |
307,692
+2.77%
|
$1,846,152
$6.5 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 1.12M shares |
|---|---|
| Other acquisition or disposition | 12.9K shares |